Clinical Trial Design Should Be Beyond Sponsor Control, UCSF Prof Urges
Executive Summary
Clinical trial design should be carried out by investigators separate from the influence of drug sponsors, Thomas Bodenheimer, MD, University of California-San Francisco, told an HHS conference on human subject protection and financial conflict of interest.